- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update
Altimmune (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced positive data from its Phase 2a study of NasoVAX intranasal influenza vaccine and provided an update on its Phase 1b study of HepTcell targeted immunotherapy in chronic hepatitis B infection. Results from the Phase 2a study of NasoVAX™ intranasal flu vaccine in 60 healthy individuals showed 100% …
Altimmune (Nasdaq:ALT), a clinical-stage immunotherapeutics company, today announced positive data from its Phase 2a study of NasoVAX intranasal influenza vaccine and provided an update on its Phase 1b study of HepTcell targeted immunotherapy in chronic hepatitis B infection. Results from the Phase 2a study of NasoVAX™ intranasal flu vaccine in 60 healthy individuals showed 100% seroprotection in the mid- and high-dose groups.
As quoted in the press release:
“We strongly believe that NasoVAX could become an important alternative vaccine for the prevention of both seasonal flu epidemics and broader flu pandemics,” said William J. Enright, president and chief executive officer of Altimmune.  “The Phase 2a data are highly encouraging, especially since antibody responses like this — with 100% seroprotection — are unique and have not been achieved with any other needle-free vaccines, including FluMist®. In addition, the excellent tolerability attained, even at the highest dose, has us excited to complete development of the quadrivalent formulation with the intention to initiate a Phase 2 study in early 2019.”
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â